Iron and Zinc Supplementation Does Not Impact Urinary Arsenic Excretion in Mexican School Children

Abstract

Objective: To examine the role of iron and zinc in arsenic excretion and metabolism in children.

Study design: An analysis of urinary arsenic (UAs) concentrations from a double-blind randomized trial originally testing the efficacy of iron and zinc for lowering blood lead levels in children. A 2 × 2 factorial design was used, with children randomized individually, stratified by sex and classroom, to receive 30?mg ferrous fumarate (n?=?148), 30?mg zinc oxide (n?=?144), iron and zinc together (n?=?148), or placebo (n?=?151). Of the 602 children enrolled, 527 completed the 6-month treatment, and 485 had both baseline and final UAs values. The baseline total UAs concentration ranged from 3.2 to 215.9?µg/L.

Results: At baseline, children in the highest tertile of serum ferritin concentration had higher excretion of dimethylarsinic acid (DMA; 1.93?±?0.86%; P?<?.05), but lower excretion of monomethylarsonic acid (-0.91?±?0.39%; P?<?.05), compared with children in the lowest tertile. In an intention-to-treat analysis, iron had no effect on arsenic methylation or UAs excretion, but children receiving zinc had lower %DMA in urine (-1.7?±?0.8; P?<?.05).

Conclusions: Iron and zinc status are not related to arsenic metabolism in children, and supplementation with these minerals has limited application in lowering arsenic concentrations.

Trial registration: ClinicalTrials.gov: NCT02346188.

Keywords: Mexico; child; iron-zinc supplementation; methylated arsenic; urinary arsenic.